Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 clients • 5 examiners • 4 art units • 0 of 5 (0%) have an AI response strategy ready
RinLaures LLC has 5 pending office actions in Biotechnology & Pharmaceuticals and 55 career applications. Its resolved allowance rate is 50.0%, meaning that allowance was reached in half of the resolved matters reported.
The firm averages 2.57 office actions per allowance. Allowed matters therefore involved repeated examination activity, while the limited application base makes the profile best suited to a focused review of this practice’s reported record. Practitioners should consider the allowance result together with the modest application history and current pending workload.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| §112 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VYAS, KEYUR ANILKUMAR | 1 | 50.0% | +58.7% |
| KNIGHT, TERESA E | 1 | 66.1% | +48.1% |
| BURKHART, MICHAEL D | 1 | 62.4% | +11.8% |
| BREEN, KIMBERLY CATHERINE | 1 | 23.8% | +56.3% |
| EDWARDS, JESSICA FAYE | 1 | 38.3% | +47.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17904119 | BIOCATALYST ADAPTATION AS LOAD FOLLOWING SOLUTION | BREEN, KIMBERLY CATHERINE | 29d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17289377 | METHOD TO USE INDUSTRIAL CO2 CONTAINING GAS FOR THE PRODUCTION OF A METHANE ENRICHED GAS COMPOSITION | EDWARDS, JESSICA FAYE | 119d overdue |
| 18050089 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | BURKHART, MICHAEL D | 35d overdue |
| 17904119 | BIOCATALYST ADAPTATION AS LOAD FOLLOWING SOLUTION | BREEN, KIMBERLY CATHERINE | 29d |
| 18609709 | INHIBITOR OF SUV39H1 HISTONE METHYLTRANSFERASE FOR USE IN CANCER COMBINATION THERAPY | VYAS, KEYUR ANILKUMAR | — |
| 18568457 | METHODS OF EUKARYOTIC GENE EXPRESSION | KNIGHT, TERESA E | — |
| Client (Assignee) | Pending OAs |
|---|---|
| INSERM | 1 |
| University of Cambridge | 1 |
| JPV01 LTD. | 1 |
| ELECTROCHAEA GMBH | 1 |
| Hitachi | 1 |
| Art Unit | Apps |
|---|---|
| 1657 | 2 |
| 1637 | 1 |
| 1634 | 1 |
| 1638 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18609709 | INHIBITOR OF SUV39H1 HISTONE METHYLTRANSFERASE FOR USE IN CANCER COMBINATION THERAPY | INSERM | VYAS, KEYUR ANILKUMAR | 1637 | §103DP | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18568457 | METHODS OF EUKARYOTIC GENE EXPRESSION | Cambridge Enterprise Limited | KNIGHT, TERESA E | 1634 | §112 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18050089 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | Jpv01 Ltd. | BURKHART, MICHAEL D | 1638 | Other | Final Rejection | 35d overdue | Pending | Oct 27, 2022 |
| 17904119 | BIOCATALYST ADAPTATION AS LOAD FOLLOWING SOLUTION | Electrochaea GmbH | BREEN, KIMBERLY CATHERINE | 1657 | §103 | Final Rejection | 29d | Pending | Aug 12, 2022 |
| 17289377 | METHOD TO USE INDUSTRIAL CO2 CONTAINING GAS FOR THE PRODUCTION OF A METHANE ENRICHED GAS COMPOSITION | Hitachi, Ltd. | EDWARDS, JESSICA FAYE | 1657 | §103 | Final Rejection | 119d overdue | Pending | Apr 28, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial50.0% of resolved applications prosecuted by Rinlaures LLC were allowed, across 55 applications in USPTO records.
2.57 office actions per allowed application on average.
5 pending office actions as of October 2026, for 5 clients, before 5 examiners in 4 art units.
